

Cahill Represents Initial Purchaser in €825 Million Offering for Catalent Pharma Solutions, Inc.

Date: 03/02/20

Cahill represented the initial purchaser in connection with a Rule 144A European offering of €825,000,000 aggregate principal amount of 2.375% senior notes due 2028 by Catalent Pharma Solutions, Inc., a multinational corporation involved in technology and development for drugs, biologics and consumer health products. Proceeds from the offering were used to refinance existing indebtedness and for other general corporate purposes.

Attorney

Joshua D. Goldberg